Sitagliptin combined with metformin — Competitive Intelligence Brief

Sitagliptin combined with metformin (Sitagliptin combined with metformin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor combined with biguanide. Area: Diabetes.

marketed DPP-4 inhibitor combined with biguanide DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I Diabetes Small molecule

Target snapshot

Sitagliptin combined with metformin (Sitagliptin combined with metformin) — Sun Yat-sen University. Sitagliptin inhibits DPP-4 to increase incretin levels and insulin secretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sitagliptin combined with metformin TARGET	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Saxagliptin + Metformin	Saxagliptin + Metformin	AstraZeneca	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor combined with biguanide class)

1. Sun Yat-sen University · 1 drug in this class